Bifunctional phage-based pretargeted imaging of human prostate carcinoma

Nuclear Medicine and Biology

Volumn 36, Issue 7, 2009, Pages 789-800

  Newton Northup, Jessica R ^a   Figueroa, Said D ^a   Quinn, Thomas P ^a,b   Deutscher, Susan L ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bacteriophage; Bifunctional phage; Prostate cancer; Radioimaging; Three step pretargeting; Two step pretargeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; INDIUM 111; NANOPARTICLE; PENTETATE INDIUM IN 111; PENTETIC ACID; PEPTIDE; STREPTAVIDIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BIOTINYLATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PROSTATE CARCINOMA; PROSTATE TUMOR; SCID MOUSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BACTERIOPHAGES; CELL LINE, TUMOR; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 69249216462     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.04.010     Document Type: Article

References (60)

1. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
2. Kaminski M.S., Estes J., Zasadny K.R., Francis I.R., Ross C.W., Tuck M., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 (2000) 1259-1266
3. 111In-DTPA-trastuzumab. Br J Pharmacol 143 (2004) 99-106
4. 18F-FDG PET. J Nucl Med 47 (2006) 793-796
5. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 (2006) 2276-2282
6. Palm S., Back T., Claesson I., Danielsson A., Elgqvist J., Frost S., et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 69 (2007) 572-579
7. Robinson M.K., Shaller C., Garmestani K., Plascjak P.S., Hodge K.M., Yuan Q.A., et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 14 (2008) 875-882
8. 213Bi (Alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 68 (2008) 3873-3880
9. Mattes M.J., and Goldenberg D.M. Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur J Nucl Med Mol Imaging 35 (2008) 1249-1258
10. Reilly R.M. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J Nucl Med 47 (2006) 196-199
11. Goldenberg D.M., and Sharkey R.M. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50 (2006) 248-264
12. Boerman O.C., van Schaijk F.G., Oyen W.J., and Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44 (2003) 400-411
13. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43 (2002) 693-713
14. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97 (2000) 1802-1807
15. 212Bi generator. Nucl Med Biol 32 (2005) 741-747
16. Wangler C., Moldenhauer G., Eisenhut M., Haberkorn U., and Mier W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem 19 (2008) 813-820
17. Pan H., Han L., Chen W., Yao M., and Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release 125 (2008) 228-235
18. Nobs L., Buchegger F., Gurny R., and Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 17 (2006) 139-145
19. Natarajan A., Xiong C.Y., Gruettner C., DeNardo G.L., and DeNardo S.J. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm 23 (2008) 82-91
20. Forero-Torres A., Shen S., Breitz H., Sims R.B., Axworthy D.B., Khazaeli M.B., et al. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 20 (2005) 379-390
21. Corneillie T.M., Whetstone P.A., and Meares C.F. Irreversibly binding anti-metal chelate antibodies: artificial receptors for pretargeting. J Inorg Biochem 100 (2006) 882-890
22. Barbet J., Kraeber-Bodere F., and Chatal J.F. What can be expected from nuclear medicine tomorrow?. Cancer Biother Radiopharm 23 (2008) 483-504
23. Newton J.R., Miao Y., Deutscher S.L., and Quinn T.P. Melanoma imaging with pretargeted bivalent bacteriophage. J Nucl Med 48 (2007) 429-436
24. Zou J., Dickerson M.T., Owen N.K., Landon L.A., and Deutscher S.L. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep 31 (2004) 121-129
25. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10 (2000) 435-442
26. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12 (1996) 697-715
27. Newton J.R., Kelly K.A., Mahmood U., Weissleder R., and Deutscher S.L. In vivo selection of phage for the optical imaging PC-3 human prostate carcinoma in mice. Neoplasia 8 (2006) 772-780
28. Kelly K.A., Waterman P., and Weissleder R. In vivo imaging of molecularly targeted phage. Neoplasia 8 (2006) 1011-1018
29. Segers J., Laumonier C., Burtea C., Laurent S., Elst L.V., and Muller R.N. From phage display to magnetophage, a new tool for magnetic resonance molecular imaging. Bioconjug Chem 18 (2007) 1251-1258
30. Rusckowski M., Gupta S., Liu G., Dou S., and Hnatowich D.J. Investigations of a (99m)Tc-labeled bacteriophage as a potential infection-specific imaging agent. J Nucl Med 45 (2004) 1201-1208
31. Rusckowski M., Gupta S., Liu G., Dou S., and Hnatowich D.J. Investigation of four (99m)Tc-labeled bacteriophages for infection-specific imaging. Nucl Med Biol 35 (2008) 433-440
32. Schechter B., Silberman R., Arnon R., and Wilchek M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem 189 (1990) 327-331
33. Wilbur D.S., Hamlin D.K., Buhler K.R., Pathare P.M., Vessella R.L., Stayton P.S., et al. Streptavidin in antibody pretargeting: 2. Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem 9 (1998) 322-330
34. Wilbur D.S., Hamlin D.K., Sanderson J., and Lin Y. Streptavidin in antibody pretargeting: 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization. Bioconjug Chem 15 (2004) 1454-1463
35. Smith G.P. Lab homepage. http://www.biosci.missouri.edu/smithGP/ University of Missouri-Columbia
36. Jin X., Newton J.R., Montgomery-Smith S., and Smith G. A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques 46 (2009) 175-182
37. Smith G.P. Kinetics of amine modification of proteins. Bioconjug Chem 17 (2006) 501-506
38. Silber H.B., Ghajari N., and Maraschin V. Eu(III) complexation constants with glutamine and serine in aqueous methanol. J Alloys Compd (2000) 112-115
39. Savinainen K.J., Saramaki O.R., Linja M.J., Bratt O., Tammela T.L., Isola J.J., et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 160 (2002) 339-345
40. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res 13 (2007) 6070-6079
41. Muller W.A., Weigl S.A., Deng X., and Phillips D.M. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178 (1993) 449-460
42. Newman P.J. The biology of PECAM-1. J Clin Invest 99 (1997) 3-8
43. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., and Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97 (2000) 14608-14613
44. di Tomaso E., Capen D., Haskell A., Hart J., Logie J.J., Jain R.K., et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 65 (2005) 5740-5749
45. Merril C.R., Scholl D., and Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2 (2003) 489-497
46. Geier M.R., Trigg M.E., and Merril C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246 (1973) 221-223
47. Inchley C.J., and Howard J.G. The immunogenicity of phagocytosed T4 bacteriophage: cell replacement studies with splenectomized and irradiated mice. Clin Exp Immunol 5 (1969) 189-198
48. Inchley C.J. The activity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol 5 (1969) 173-187
49. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163 (2003) 1801-1815
50. Rosebrough S.F. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol 20 (1993) 663-668
51. Sabatino G., Chinol M., Paganelli G., Papi S., Chelli M., Leone G., et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem 46 (2003) 3170-3173
52. Hamblett K.J., Press O.W., Meyer D.L., Hamlin D.K., Axworthy D., Wilbur D.S., et al. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjug Chem 16 (2005) 131-138
53. Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., and Larson S.M. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 47 (2006) 140-149
54. Landon L.A., Zou J., and Deutscher S.L. Is phage display technology on target for developing peptide-based cancer drugs?. Curr Drug Discov Technol 1 (2004) 113-132
55. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 10 (2004) 2335-2343
56. 111In-Labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med 49 (2008) 796-803
57. Kelly K.A., and Jones D.A. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 5 (2003) 437-444
58. Chen X., Sievers E., Hou Y., Park R., Tohme M., Bart R., et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7 (2005) 271-279
59. Lovric J., Bazzi H.S., Cuie Y., Fortin G.R., Winnik F.M., and Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med 83 (2005) 377-385
60. Shiohara A., Hoshino A., Hanaki K., Suzuki K., and Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol 48 (2004) 669-675